Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: The aim of JCOG1610 (randomized controlled phase III trial) was to confirm the superiority of preoperative denosumab to curettage with adjuvant local therapy for patients with giant cell tumor of bone without possible post-operative large bone defect.
Methods: The primary endpoint was relapse-free survival and the total sample size was set at 106 patients. Patient accrual began in October 2017. However, the accrual was terminated in December 2020 due to a recommendation from the Data and Safety Monitoring Committee because of poor patient accrual. Now, we report the descriptive results obtained in this study.
Results: A total of 18 patients had been registered from 13 Japanese institutions at the time of termination on December 2020. Eleven patients were assigned to Arm A (curettage and adjuvant local therapy) and 7 to Arm B (preoperative denosumab, curettage and adjuvant local therapy). Median follow-up period was 1.6 (range: 0.5-2.8) years. Protocol treatment was completed in all but one patient in Arm A who had a pathological fracture before surgery. All patients in Arm B were treated with five courses of preoperative denosumab. Relapse-free survival proportions in Arm A and B were 90.0% (95% confidence interval: 47.3-98.5) and 100% (100-100) at 1 year, and 60.0% (19.0-85.5) and 62.5% (14.2-89.3) at 2 years, respectively [hazard ratio (95% confidence interval): 1.51 (0.24-9.41)].
Conclusion: In terms of relapse-free survival, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jjco/hyac071 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combined use of 3D-printed customized prostheses and denosumab for the treatment of giant cell tumor of the distal radius: clinical outcomes and efficacy.
Front Oncol
August 2025
Department of Orthopedics, Orthopaedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Objective: To investigate the short- and mid-term clinical efficacy of denosumab combined with 3D-printed prosthesis in the treatment of patients with giant cell tumor of the distal radius.
Methods: From January 2016 to January 2022, 20 patients with giant cell tumor of the distal radius underwent denosumab treatment combined with 3D-printed prosthetic reconstruction at our hospital. This study evaluates the short- and mid-term efficacy by analyzing clinical cases where denosumab was used preoperatively, followed by 3D-printed biological prosthesis reconstruction of the distal radius tumor segment defect.
Radical resection of a giant cell tumor of the distal ulna and reconstruction with a 3D-printed distal ulnar prosthesis: A case report.
Medicine (Baltimore)
July 2025
Department of Orthopedics, The Third Hospital of Mianyang·Sichuan Mental Health Center, Mianyang, China.
Rationale: Giant cell tumors (GCTs) of the distal ulna are rare. Despite their benign nature, these tumors can exhibit local aggressiveness and have the potential to recur after undergoing conventional treatment involving curettage and bone grafting. For aggressive GCTs, radical resection is more suitable.
View Article and Find Full Text PDFWhich Clinical Factors Are Associated with the Post-Denosumab Size Reduction of Giant Cell Tumors? The Korean Society of Spinal Tumor (KSST) Multicenter Study 2023-02.
Cancers (Basel)
June 2025
Department of Orthopaedic Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Background/objectives: Denosumab has been considered effective for downstaging giant cell tumor of bone (GCTB), implying that it lowers the Campanacci grade rather than reducing tumor size. Preoperative tumor shrinkage holds therapeutic value by decreasing surgical complications. While previous studies have observed lesion shrinkage in some patients, no study has identified the types of patients likely to show treatment response.
View Article and Find Full Text PDFModerate-to-severe hypercalcemia secondary to primary hyperparathyroidism refractory to conventional treatment (therapeutic management with denosumab): case report and literature review.
Pan Afr Med J
June 2025
Sección de Endocrinología y Nutrición, Hospital Virgen de los Lirios, Alcoy, Alicante, España.
Severe hypercalcemia resistant to conventional medical treatment is a rare complication of primary hyperparathyroidism, and published information on the use of denosumab in patients with this condition is limited. This article aims to review the current literature on the utility of denosumab as a hypocalcemic agent in the context of a real clinical case. We present the case of an 87-year-old woman with nonspecific symptoms of constipation and asthenia who was diagnosed with severe hypercalcemia secondary to primary hyperparathyroidism.
View Article and Find Full Text PDFImpact of Frailty and Other Factors as Estimated by HU to Predict Response to Anabolic Bone Medications.
J Clin Med
May 2025
Departement of Neurologic Surgery, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
Bone health optimization is a key component of the preoperative management of spine surgery patients, as poor bone quality increases the odds of mechanical complications. The present study aimed to achieve the following: (1) compare the relative efficacy of current osteoporosis medications in improving bone quality; (2) identify factors influencing treatment response in preoperative spine surgery patients. Patients treated at a single, multisite institution who received osteoporosis treatment were identified.
View Article and Find Full Text PDF